Evaluate the Efficacy and Safety of DWP05195 in Subjects With Post-Herpetic Neuralgia

Phase 2

Completed

• Conditions: Postherpetic Neuralgia
• Interventions: Drug: Control; Drug: DWP05195

• Registration Number: NCT01557010
• Lead Sponsor: Daewoong Pharmaceutical Co. LTD.

Brief Summary

The purpose of this study is to evaluate efficacy, safety of administered DWP05195 in Postherpetic Neuralgia.

Detailed Description

Not available

Study Timeline

• Study Start: 2012-03
• Study First Submitted: 2012-03-14
• Study First Submitted QC: 2012-03-15
• Study First Posted: 2012-03-19
• Primary Completion: 2013-11
• Study Completion: 2013-12
• Status Verified: 2014-02
• Last Update Submitted: 2014-02-19
• Last Update Posted: 2014-02-21

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 140

Inclusion Criteria

• Male or Female subjects aged 20 to 80 years
• Subjects with symptoms of neuropathic pain associated with postherpetic neuralgia(PHN).
• Subjects must have pain present for > 3 months after healing of the acute herpes zoster skin rash.

Exclusion Criteria

• Other severe pain that may potentially confound pain assessment.
• Subjects with symptoms of neuropathic pain applied Medical Equipment
• Within 2 years: Subjects were diagnosed with cancer

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Treatment D	Control	-
Treatment B	DWP05195	-
Treatment A	DWP05195	-
Treatment C	DWP05195	-

Primary Outcome Measures

Name	Time	Method
Endpoint change from the baseline after administered 8 weeks mean pain score based on the Numerical pain Rating Scale(NPRS) from the subject's daily pain diary	8 weeks